A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions
Abstract
1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sundd, P.; Gladwin, M.T.; Novelli, E.M. Pathophysiology of sickle cell disease. Annu. Rev. Pathol. 2019, 14, 263–292. [Google Scholar] [CrossRef] [PubMed]
- Sparkenbaugh, E.; Pawlinski, R. Interplay between coagulation and vascular inflammation in sickle cell disease. Br. J. Hematol. 2013, 162, 3–14. [Google Scholar] [CrossRef] [PubMed]
- Elendu, C.; Amaechi, D.C.; Alakwe-Ojimba, C.E.; Elendu, T.C.; Elendu, R.C.; Ayabazu, C.P.; Aina, T.O.; Aborisade, O.; Adenikinju, J.S. Understanding Sickle cell disease: Causes, symptoms, and treatment options. Medicine 2023, 102, e35237. [Google Scholar] [CrossRef] [PubMed]
- Rees, D.C.; Brousse, V.A.M.; Brewin, J.N. Determinants of severity in sickle cell disease. Blood Rev. 2022, 56, 100983. [Google Scholar] [CrossRef]
- Rees, D.C.; Robinson, S.; Howard, J. How I manage red cell transfusions in patients with sickle cell disease. Br. J. Haematol. 2018, 180, 607–617. [Google Scholar] [CrossRef] [PubMed]
- Pirenne, F.; Yazdanbakhsh, K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood 2018, 131, 2773–2781. [Google Scholar] [CrossRef] [PubMed]
- Kelly, S.; Deng, X.; Hopper, C.; Style, L. A pilot randomized trial of red blood cell transfusion for acute treatment of vaso-occlusive pain episodes in sickle cell disease. Br. J. Haematol. 2015, 171, 288–290. [Google Scholar] [CrossRef]
- Adams Rj McKie, V.C.; Hsu, L.; Files, B.; Vichinsky, E.; Pegelow, C.; Abboud, M.; Gallagher, D.; Kutlar, A.; Nichols, F.T.; Bonds, D.R.; et al. Prevention of first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med. 1998, 339, 5–11. [Google Scholar] [CrossRef]
- Ware, R.E.; Davis, B.R.; Schultz, W.H.; Brown, R.C.; Aygun, B.; Sarnaik, S.; Odame, I.; Fuh, B.; George, A.; Owen, W.; et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anemia (TWiTCH): A multicentric, open-label, phase 3, non-inferiority trial. Lancet 2016, 387, 661–670. [Google Scholar] [CrossRef]
- Narbey, D.; Habibi, A.; Chadebech, P.; Mekontso-Dessap, A.; Khellaf, M.; Lelièvre, J.D.; Godeau, B.; Michel, M.; Galactéros, F.; Djoudi, R.; et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am. J. Hematol. 2017, 92, 1340–1348. [Google Scholar] [CrossRef]
- Pirenne, F.; Pondarré, C. Alloimmunization and hyperhemolysis in sickle cell disease. Hematology 2023, 2023, 653–659. [Google Scholar] [CrossRef] [PubMed]
- Fasano, R.M.; Miller, M.J.; Chonat, S.; Stowell, S.R. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease. Transfus. Clin. Biol. 2019, 26, 94–98. [Google Scholar] [CrossRef] [PubMed]
- Banks, M.; Shikle, J. Hyperhemolysis syndrome in patients with sickle cell disease. Arch. Pathol. Lab. Med. 2017, 142, 1425–1427. [Google Scholar] [CrossRef] [PubMed]
- Jacobs, J.W.; Stephens, L.D.; Allen, E.S.; Binns, T.C.; Booth, G.S.; Hendrickson, J.E.; Karafin, M.S.; Tormey, C.A.; Woo, J.S.; Adkins, B.D. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. Br. J. Haematol. 2023, 201, 1025–1032. [Google Scholar] [CrossRef]
- Shankar, K.; Shah, D.; Huffman, D.L.; Peterson, C.; Bhagavatula, R. Hyperhemolysis Syndrome in a Patient With Sickle Cell Disease and Acute Chest Syndrome. Cureus 2021, 13, e13017. [Google Scholar] [CrossRef]
- Win, N.; New, H.; Lee, E.; de la Fuente, J. Hyperhemolysis syndrome in sickle cell disease: A case report (recurrent episode) and literature review. Transfusion 2008, 48, 1231–1238. [Google Scholar] [CrossRef] [PubMed]
- Trivedi, K.; Abbas, A.; Kazmi, R.; Shaaban, H.; Miller, R. Hyperhemolytic crisis following transfusion in sickle cell disease with acute hepatic crisis: A case report. Cureus 2022, 14, e27844. [Google Scholar] [CrossRef] [PubMed]
- Kalter, J.A.; Gupta, R.; Greenberg, M.R.; Miller, A.J.; Allen, J. Hyperhemolysis Syndrome in a Patient with Sickle Cell Disease: A Case Report. Clin. Pract. Cases Emerg. Med. 2021, 5, 101–104. [Google Scholar] [CrossRef]
- Win, N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev. Hematol. 2009, 2, 111–115. [Google Scholar] [CrossRef]
- Roumenina, L.T.; Bartolucci, P.; Pirenne, F. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Transfus. Med. Rev. 2019, 33, 225–230. [Google Scholar] [CrossRef]
- Madu, A.J.; Ugwu, A.O.; Efobi, C. Hyperhemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs. Med. Princ. Pract. 2021, 30, 236–243. [Google Scholar] [CrossRef]
- Menakuru, S.R.; Priscu, A.; Dhillon, V.; Salih, A. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature. Hematol. Rep. 2022, 14, 235–239. [Google Scholar] [CrossRef]
- Dumas, G.; Habibi, A.; Onimus, T.; Merle, J.C.; Razazi, K.; Mekontso Dessap, A.; Galactéros, F.; Michel, M.; Frémeaux Bacchi, V.; Noizat Pirenne, F.; et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 2016, 127, 1062–1064. [Google Scholar] [CrossRef]
- Vichinsky, E.; Hoppe, C.C.; Ataga, K.I.; Ware, R.E.; Nduba, V.; El-Beshlawy, A.; Hassab, H.; Achebe, M.M.; Alkindi, S.; Brown, R.C.; et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N. Engl. J. Med. 2019, 381, 509–519. [Google Scholar] [CrossRef]
- Kuriri, F.A. Hope on the Horizon: New and Future Therapies for sickle cell disease. J. Clin. Med. 2023, 12, 5692. [Google Scholar] [CrossRef] [PubMed]
- Chou, S.T.; Alsawas, M.; Fasano, R.M.; Field, J.J.; Hendrickson, J.E.; Howard, J.; Kameka, M.; Kwiatkowski, J.L.; Pirenne, F.; Shi, P.A.; et al. American Society of Hematology 2020 guidelines for sickle cell disease: Transfusion support. Blood Adv. 2020, 4, 327–355. [Google Scholar] [CrossRef]
- Ballas, S.K.; Kuypers, F.A.; Gordeuk, V.R.; Hankins, J.S.; Thompson, A.A.; Vichinsky, E. Time to rethink haemoglobin threshold guidelines in sickle cell disease. Br. J. Haematol. 2021, 195, 518–522. [Google Scholar] [CrossRef] [PubMed]
- Shaulov, A.; Rund, D.; Filon, D.; Nachmias, B.; Khalili, A.; Manny, N.; Zelig, O. Successful treatment with plasma exchange in life-threatening hyperhemolytic syndrome unrelated to sickle cell disease. Transfusion 2023, 63, 1100–1106. [Google Scholar] [CrossRef] [PubMed]
Days | Baseline | P+ 1 | P+ 3 | P+ 9 | P+ 11 | P+ 16 | P+ 24 | P+ 38 |
---|---|---|---|---|---|---|---|---|
Hgb (g/L) | 97 | 65 | 52 | 39 | 35 | 67 | 77 | 81 |
LDH (U/L) | 300 | 867 | 851 | 4221 | 2432 | 1329 | 799 | 642 |
tBi (umol/L) | 39.8 | NA | 185.7 | 437.3 | 204 | 98.5 | 72.3 | 58.5 |
diBi (umol/L) | 13.5 | NA | 86.1 | 249.8 | 170.9 | 82 | 60.1 | 41.3 |
CRP (mg/L) | 4.4 | NA | NA | 168 | 104 | 52 | 5.98 | |
Haptoglobin (g/L) | NA | NA | NA | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 |
Reticulocytes (G/L) | NA | NA | 154 | 247 | NA | 50 | 49 | 155 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Obajed Al-Ali, O.; Pfliegler, G.; Magyari, F.; Borics, F.; Pinczés, L.I.; Illés, Á.; Brúgós, B. A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions. Thalass. Rep. 2024, 14, 18-25. https://doi.org/10.3390/thalassrep14010003
Obajed Al-Ali O, Pfliegler G, Magyari F, Borics F, Pinczés LI, Illés Á, Brúgós B. A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions. Thalassemia Reports. 2024; 14(1):18-25. https://doi.org/10.3390/thalassrep14010003
Chicago/Turabian StyleObajed Al-Ali, Omar, György Pfliegler, Ferenc Magyari, Fanni Borics, László Imre Pinczés, Árpád Illés, and Boglárka Brúgós. 2024. "A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions" Thalassemia Reports 14, no. 1: 18-25. https://doi.org/10.3390/thalassrep14010003
APA StyleObajed Al-Ali, O., Pfliegler, G., Magyari, F., Borics, F., Pinczés, L. I., Illés, Á., & Brúgós, B. (2024). A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions. Thalassemia Reports, 14(1), 18-25. https://doi.org/10.3390/thalassrep14010003